Press

 

Press

For the latest news from EHA, please visit the section EHA Press Releases.

The media regulations and press registration information for the 18th Congress of EHA Are available.

In order to register for the Press program, please send a mail, with a copy of your press credentials attached to communication@ehaweb.org. Please mention in the subject of your e-mail: Press registration EHA18. Your credentials will be checked and when approved, you will receive an link to the online press registration.

Press Briefing Prgram
Date/Time: Friday June 14, 2013  -  8:30 - 10:00 A.M.
Location: Hall C5 Stockholmmässan, Stockholm, Sweden
Moderator: Dr Anton Hagenbeek

Press Briefing Prgram

Date/Time: Friday June 14, 2013  -  8:30 - 10:00 A.M.
Location: Hall C5 Stockholmmässan, Stockholm, Sweden
Moderator: Dr Anton Hagenbeek

Time Topic Speaker
08:30Start Press Briefing
08:30 – 08:35Introduction Dr Anton Hagenbeek, Moderator
08:35 – 08:40 “European Hematology Association”Dr Ulrich Jäger, EHA President
08:40 – 08:45 Scientific Program EHA18 including the progress in basic science in the field of childhood leukemias Dr Jorge Sierra, Chair SPC
08:45 – 08:50Questions by media representatives
08:50 – 08:55 View on small molecules in lymphoma/leukemia Dr Wyndham H. Wilson
08:55 – 09:00Questions by media representatives
09:00 – 09:05Age and Aging in blood disorders Dr Pieter Sonneveld
09:05 – 09:10Questions by media representatives
09:10 – 09:15Efficacy, Safety and Quality of Life in MM-003, a phase3, multicenter, randomized, open label study of Pomalidomide (POM) + low-dose Dexamethasone (lodex) vs high-dose Dexamethasone (hidex) in relapsed/refractory multiple myeloma Dr Jesus San Miguel
09:15 – 09:20Questions by media representatives
09:20 – 09:25Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma- an open label, dose escalation followed by open label-extension in a single-arm phase I/II study Dr Henk Lokhorst
09:25 – 09:30Questions by media representatives
09:30 – 09:35 Potential use of minihepcidins as therapeutics to prevent iron overload Dr Elizabeta Nemeth
09:35 – 09:40Questions by media representatives
09:40 – 09:45JAK-STAT pathway in malignant and non-malignant cells contributes to myeloproliferative neoplasms pathogenesis and therapeutic responseDr Ross L. Levine
09:45 – 09:50Questions by media representatives
09:50 – 09:55Obinutuzumab (GA101) or Rituximab (R) + Chlorambucil (CLB) versus CLB alone in patients with Chronic Lymphocytic Leukemia and pre-existing medical conditions (comorbidities): Final stage 1 results of the CLL11 phase 3 trial Dr Valentin Goede
09:55 – 10:00 Questions by media representatives
10:00 Conclusion

Press contact: 

EHA Executive Office
Communication & Press

Ineke van der Beek 

Jon Tarifa

 

 

This website uses cookies. By continuing to browse this website you are agreeing to our use of cookies.
Find out more by reading our General Terms & Conditions. Accept Cookies